Group 1 - Vanda Pharmaceuticals Inc. reported a disappointing 4Q25 with a GAAP EPS of -$2.39, missing consensus by approximately $1.07 [1] - The company's revenue for the quarter was $57.22 million, which fell short of expectations by about $2.05 million [1] Group 2 - The article emphasizes the importance of evaluating the science behind drug candidates, the competitive landscape, clinical trial design, and potential market opportunities in the biotech sector [1] - It highlights the need for careful scrutiny in biotech investments, where breakthrough science can lead to significant returns but also carries inherent risks [1]

Sales and Market Focus - Vanda Pharmaceuticals reported a focus on generating U.S. sales of Fanapt (iloperidone) for schizophrenia and bipolar I disorder treatment[11] - Vanda Pharmaceuticals Inc. is focused on generating U.S. sales of Fanapt (iloperidone) for schizophrenia and bipolar I disorder, with ongoing efforts to increase market awareness and acceptance[1] - Vanda is working to increase market awareness and acceptance of HETLIOZ for Non-24 and Smith-Magenis syndrome[11] - HETLIOZ (tasimelteon) sales are being impacted by existing and potential generic competition, with a focus on expanding its use for Non-24-Hour Sleep-Wake Disorder and Smith-Magenis syndrome[1] - Vanda is working to commercialize PONVORY (ponesimod) for relapsing forms of multiple sclerosis in the U.S.[11] - Vanda is working to commercialize PONVORY (ponesimod) for relapsing forms of multiple sclerosis and is pursuing FDA approval for additional indications[1] Regulatory Approvals - The company aims to obtain FDA approval for Bysanti (milsaperidone) for bipolar I disorder, schizophrenia, and major depressive disorder[11] - The company is seeking FDA approval for Bysanti (milsaperidone) for bipolar I disorder, schizophrenia, and major depressive disorder (MDD)[1] - Vanda is seeking FDA approval for NEREUS (tradipitant) for motion-induced vomiting and gastroparesis[11] - Regulatory approval for new product candidates, including NEREUS and imsidolimab, remains uncertain, impacting future growth prospects[1] Competition and Market Risks - HETLIOZ (tasimelteon) sales are expected to face challenges due to existing and potential generic competition[11] - The company faces risks related to pricing and reimbursement policies in the U.S., impacting product sales[17] - The company is subject to competition that may affect the commercial success of its products[17] - The company faces challenges with reimbursement and patient access for HETLIOZ, which may affect sales performance[1] - The company is dependent on the commercial success of its products, including Fanapt, HETLIOZ, PONVORY, and NEREUS, amid competitive pressures[1] Operational Risks - Vanda relies on third-party manufacturers for product supply, which poses risks to production capacity[17] - Vanda relies on third-party manufacturers for product supply, which poses risks to meeting demand and quality standards[1] - Global economic conditions and health crises may adversely impact Vanda's business operations[17] - The company is subject to various risks, including pricing and reimbursement policies, which could materially affect its financial condition and operations[1] Human Resources - Vanda's ability to attract and retain key personnel is critical for its research and development efforts[1]

Core Insights - Vanda Pharmaceuticals reported a quarterly loss of $0.46 per share, significantly better than the Zacks Consensus Estimate of a loss of $2.18, representing an earnings surprise of +78.85% [1] - The company posted revenues of $57.22 million for the quarter ended December 2025, missing the Zacks Consensus Estimate by 2.78%, but showing an increase from $53.19 million year-over-year [2] - Vanda shares have underperformed the market, losing about 15.9% since the beginning of the year compared to the S&P 500's gain of 1.4% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.24 on revenues of $64 million, and for the current fiscal year, it is -$1.47 on revenues of $275.85 million [7] - The estimate revisions trend for Vanda was favorable ahead of the earnings release, resulting in a Zacks Rank 2 (Buy) for the stock, indicating expected outperformance in the near future [6] Industry Context - The Medical - Biomedical and Genetics industry, to which Vanda belongs, is currently in the top 35% of over 250 Zacks industries, suggesting a favorable outlook for stocks within this sector [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Financial Data and Key Metrics Changes - Total revenues for the full year 2025 were $216.1 million, a 9% increase compared to $198.8 million for 2024 [18] - Net loss for the full year 2025 was $220.5 million, compared to a net loss of $18.9 million for 2024, primarily due to a one-time, non-cash income tax charge [21][22] - Operating expenses for the full year 2025 were $367.3 million, an increase from $239.4 million in 2024 [24] Business Line Data and Key Metrics Changes - Fanapt net product sales were $117.3 million for 2025, a 24% increase from $94.3 million in 2024, driven by a 28% rise in total prescriptions and a 149% surge in new-to-brand prescriptions [5][19] - Hetlioz net product sales were $71.4 million for 2025, a 7% decrease from $76.7 million in 2024, impacted by generic competition [20] - Ponvory net product sales were $27.4 million for 2025, a 2% decrease from $27.8 million in 2024 [21] Market Data and Key Metrics Changes - Fanapt was one of the fastest-growing atypical antipsychotics in the market throughout 2025, with total prescriptions increasing by 36% in Q4 2025 compared to Q4 2024 [37] - The total addressable market for the antipsychotic category was estimated at approximately $20 billion in 2025 [7] - The global long-acting injectable antipsychotic market is projected to be in the $6 billion-$7 billion range for 2025, with strong growth expected [12] Company Strategy and Development Direction - The company plans to initiate a dedicated phase III program for Nereus in the first half of 2026, targeting the GLP-1 agonist market [7] - Vanda aims to strengthen its psychiatry franchise with the anticipated approval of Bysanti for bipolar I disorder and schizophrenia, with a PDUFA target action date of February 21, 2026 [8][17] - The company is committed to delivering innovative therapies and long-term value for patients and shareholders [17] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the commercial launch of Nereus and the potential for significant market opportunities in motion sickness [6] - The company expects total revenues of $230 million-$260 million from current marketed products in 2026, indicating continued growth [17][40] - Management highlighted the importance of strategic investments in commercial infrastructure to support long-term market leadership [26] Other Important Information - The company recorded a valuation allowance of $113.7 million against all deferred tax assets, which is a one-time, non-cash charge [22][24] - Cash, cash equivalents, and marketable securities as of December 31, 2025, were $263.8 million, a decrease of $110.8 million compared to the previous year [26] Q&A Session Summary Question: Can you characterize any FDA communication on outstanding issues related to Bysanti? - Management remains optimistic for an on-time approval and will provide more details on the launch strategy once commercial supplies are ready [48] Question: What is the expected commercial infrastructure for imsidolimab? - A small specialty sales force will be key for addressing the rare dermatological condition associated with imsidolimab [50] Question: Can you provide details on promotional activities for Fanapt and Bysanti? - Current direct-to-consumer campaigns focus on Fanapt and Ponvory, with plans for a dedicated campaign for Bysanti upon its launch [52] Question: When will Nereus be commercially available? - Commercial materials are expected to be ready by late Q2 or early Q3 2026 [54] Question: What is the expected pricing for Nereus? - Pricing is not yet communicated, but it is expected to be at a premium compared to existing treatments for motion sickness [71]

Financial Data and Key Metrics Changes - Total revenues for the full year 2025 were $216.1 million, a 9% increase compared to $198.8 million for 2024 [18] - Net product sales for Fanapt were $117.3 million, a 24% increase from $94.3 million in 2024 [18] - The company recorded a net loss of $220.5 million for 2025, compared to a net loss of $18.9 million in 2024 [21] - Operating expenses for 2025 were $367.3 million, up from $239.4 million in 2024 [24] Business Line Data and Key Metrics Changes - Fanapt's total prescriptions increased by 28% in 2025 compared to 2024 [19] - HETLIOZ net product sales were $71.4 million for 2025, a 7% decrease from $76.7 million in 2024 due to generic competition [20] - Ponvory net product sales were $27.4 million for 2025, a 2% decrease from $27.8 million in 2024 [21] Market Data and Key Metrics Changes - The total addressable market for the antipsychotic category is estimated at approximately $20 billion in 2025 [7] - The long-acting injectable antipsychotic market is projected to be in the $6 billion-$7 billion range for 2025 [12] Company Strategy and Development Direction - The company plans to initiate a dedicated phase III program for Nereus in the first half of 2026, targeting the GLP-1 agonist market [7] - Vanda aims to strengthen its psychiatric franchise with the anticipated approval of Bysanti for bipolar I disorder and schizophrenia [17] - The company is focused on expanding its commercial infrastructure and brand visibility through targeted sponsorships and marketing programs [26][36] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the commercial launch of Nereus and the potential for significant market opportunities in motion sickness [6] - The company expects total revenues of $230 million-$260 million from current marketed products in 2026, indicating continued growth [40] - Management highlighted the importance of addressing unmet medical needs in major depressive disorder and social anxiety disorder through innovative therapies [10][12] Other Important Information - The company recorded a one-time, non-cash income tax charge of $113.7 million for the valuation allowance against deferred tax assets [22] - Cash, cash equivalents, and marketable securities as of December 31, 2025, were $263.8 million, a decrease of $110.8 million compared to the previous year [26] Q&A Session Summary Question: Can you provide updates on Bysanti's FDA review and commercial strategy? - Management indicated optimism for an on-time approval and mentioned that commercialization would begin in Q3 2026 if approved [48] Question: What is the expected commercial infrastructure for Imsidolimab? - A small specialty sales force will be dedicated to marketing Imsidolimab, focusing on dermatologists and advocacy organizations [50] Question: Can you elaborate on promotional activities for Fanapt and Bysanti? - Current direct-to-consumer campaigns focus on Fanapt and Ponvory, with plans for a dedicated campaign for Bysanti upon its launch [52] Question: When will Nereus be commercially available? - Nereus is expected to be commercially available by late Q2 or early Q3 2026 [54] Question: What is the pricing strategy for Nereus? - While a specific price has not been communicated, it is expected to be at a premium compared to existing treatments for motion sickness [71]

Financial Data and Key Metrics Changes - Total revenues for the full year 2025 were $216.1 million, a 9% increase compared to $198.8 million for 2024 [16] - Net loss for the full year 2025 was $220.5 million, compared to a net loss of $18.9 million for 2024, primarily due to a one-time, non-cash income tax charge [18][19] - Operating expenses for the full year 2025 were $367.3 million, an increase from $239.4 million in 2024 [21] Business Line Data and Key Metrics Changes - Fanapt net product sales increased by 24% to $117.3 million in 2025, driven by a 28% rise in total prescriptions and a 149% surge in new-to-brand prescriptions [5][17] - HETLIOZ net product sales decreased by 7% to $71.4 million in 2025 due to generic competition [17] - Ponvory net product sales were $27.4 million, a slight decrease of 2% compared to 2024 [18] Market Data and Key Metrics Changes - Fanapt was one of the fastest-growing atypical antipsychotics in the market throughout 2025, with total prescriptions increasing by 36% in Q4 2025 compared to Q4 2024 [31] - The global long-acting injectable antipsychotic market is projected to be valued between $6 billion and $7 billion in 2025, with strong growth expected [11] Company Strategy and Development Direction - The company plans to launch Nereus for motion sickness, which was approved in late 2025, targeting a substantial market opportunity [6] - Vanda is preparing for the commercial launch of Bysanti, with a focus on transitioning patients from Fanapt [41] - The company aims to strengthen its psychiatric franchise with ongoing clinical development programs and potential new product approvals [15] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the commercial potential of Nereus and the upcoming launch of Bysanti, anticipating continued revenue growth from existing products [15][34] - The company expects total revenues from marketed products in 2026 to be between $230 million and $260 million, indicating a growth of approximately 13% compared to 2025 [34] Other Important Information - Cash, cash equivalents, and marketable securities as of December 31, 2025, were $263.8 million, a decrease of $110.8 million compared to the previous year [23] - The company recorded a valuation allowance against all net deferred tax assets, resulting in a non-cash income tax expense of $113.7 million for 2025 [21] Q&A Session Summary Question: Can you characterize any FDA communication on Bysanti? - Management remains optimistic for an on-time approval and will provide more details on the launch strategy if approved [41][42] Question: What is the expected commercial infrastructure for Imsidolimab? - A small specialty sales force will be key for addressing the rare dermatological condition [44] Question: What promotional activities are planned for Fanapt and Bysanti? - A direct-to-consumer campaign for Fanapt and Ponvory is expected to continue, with a dedicated campaign for Bysanti planned if approved [45] Question: When will Nereus be commercially available? - Commercial materials are expected to be ready by late Q2 or early Q3 2026 [46] Question: What is the pricing strategy for Nereus? - Pricing is expected to be premium compared to existing treatments for motion sickness [65] Question: Will the phase 3 trial for tradipitant follow the same design as phase 2? - Yes, the design will be similar, using a high upfront dose of Wegovy [68]

Financial Performance - Full year 2025 net product sales for Fanapt increased by 24% to $117.3 million compared to 2024[6] - Total revenues for full year 2025 rose by 9% to $216.1 million compared to 2024[6] - In Q4 2025, total net product sales from Fanapt, HETLIOZ, and PONVORY were $57.2 million, an 8% increase from $53.2 million in Q4 2024[7] - Vanda Pharmaceuticals reported total revenues of $57.216 million for the three months ended December 31, 2025, compared to $53.185 million for the same period in 2024, representing an increase of 3.9%[29] - The net product sales for Fanapt reached $33.218 million in Q4 2025, up from $26.649 million in Q4 2024, indicating a growth of 24.5%[29] - The net loss for the twelve months ended December 31, 2025, was $220.474 million, compared to a net loss of $18.900 million for the same period in 2024[29] Cash and Assets - Cash and cash equivalents as of December 31, 2025, were $263.8 million, a decrease of $29.9 million from September 30, 2025[8] - The company’s cash and cash equivalents decreased to $84.851 million as of December 31, 2025, down from $102.316 million a year earlier[31] - Total assets decreased to $488.948 million as of December 31, 2025, compared to $656.204 million as of December 31, 2024[31] - Vanda's accumulated deficit increased to $394.766 million as of December 31, 2025, from $174.292 million a year earlier[31] Future Projections - Vanda expects total revenues in 2026 to be between $230 million and $260 million, with Fanapt net product sales projected at $150 million to $170 million[16] - The company plans to pursue FDA approval for Bysanti for bipolar I disorder and schizophrenia, with a target decision date of February 21, 2026[26] - Vanda aims to initiate the clinical program for NEREUS in the prevention of vomiting induced by Wegovy in the first half of 2026[27] - The company expects to complete the clinical study for VQW-765 in the treatment of adults with social anxiety disorder and receive results by the end of 2026[27] Research and Development - Research and development expenses increased significantly to $29.006 million in Q4 2025 from $19.840 million in Q4 2024, reflecting a rise of 46.1%[29] - The NDA for Bysanti (milsaperidone) is under FDA review, with a PDUFA target action date of February 21, 2026[6] - Vanda submitted a BLA for imsidolimab for generalized pustular psoriasis in Q4 2025[12] Market Performance - New-to-brand prescriptions for Fanapt increased by 149% for full year 2025 compared to 2024[12] - The FDA approved NEREUS (tradipitant) for motion-induced vomiting prevention, targeting approximately 65–78 million U.S. adults[4]

Core Insights - Vanda Pharmaceuticals reported a strong financial performance for the full year 2025, with total revenues increasing by 9% to $216.1 million compared to 2024, driven primarily by a 24% increase in net product sales of Fanapt® [1][2] - The company is awaiting FDA approval for Bysanti™ (milsaperidone) for bipolar I disorder and schizophrenia, with a target action date of February 21, 2026, which could expand its psychiatry franchise [1][2] - The FDA approved NEREUS™ (tradipitant) for the prevention of motion-induced vomiting, marking a significant milestone as the first new oral therapy for this condition in over 40 years [1][2] Financial Highlights - For Q4 2025, Vanda reported a net loss of $141.2 million, compared to a net loss of $4.9 million in Q4 2024, with a diluted net loss per share of $2.39 [2][4] - The provision for income taxes in Q4 2025 was $103.2 million, influenced by a non-cash charge of $113.7 million against deferred tax assets [1][2] - Full year 2025 net loss was $220.5 million, compared to $18.9 million in 2024, with a diluted net loss per share of $3.74 [2][4] Operational Highlights - Fanapt® saw a 24% increase in net product sales for the full year 2025, totaling $117.3 million, supported by a 28% rise in total prescriptions [1][2] - The company launched a direct-to-consumer campaign in 2025, enhancing brand awareness for Fanapt® and PONVORY® [1][2] - Vanda is preparing for the commercial launch of NEREUS™ and plans to initiate a Phase III program for its use in preventing vomiting from GLP-1 analogs in the first half of 2026 [1][2] Regulatory & Clinical Development - Vanda received a decision letter from the FDA regarding the sNDA for HETLIOZ® for jet lag disorder, indicating it cannot be approved in its current form [2] - Ongoing clinical studies include a Phase III study of the long-acting injectable formulation of iloperidone for schizophrenia and a Phase III study of VQW-765 for social anxiety disorder [2] - The company submitted a BLA for imsidolimab for generalized pustular psoriasis in Q4 2025 [2] 2026 Financial Guidance - Vanda expects total revenues for 2026 to be between $230 million and $260 million, with Fanapt® net product sales projected to be between $150 million and $170 million [2]

Core Viewpoint - Vanda Pharmaceuticals Inc. will release its financial results for the fourth quarter and full year 2025 on February 11, 2026, after market close [1]. Group 1: Financial Results Announcement - The financial results will be discussed during a conference call scheduled for 4:30 PM ET on February 11, 2026 [2]. - The conference call will be accessible via a domestic dial-in number (1-888-596-4144) and an international number (1-646-968-2525) with a passcode of 8728050 [2]. Group 2: Conference Call Details - The conference call will be broadcast live and archived on Vanda's website, encouraging investors to register and prepare in advance [3]. - A replay of the conference call will be available starting at 8:30 PM ET on February 11, 2026, until 11:59 PM ET on February 18, 2026, with specific call-in numbers for domestic (1-800-770-2030) and international (1-609-800-9909) callers [4]. Group 3: Company Overview - Vanda Pharmaceuticals Inc. is a global biopharmaceutical company focused on developing and commercializing innovative therapies to meet high unmet medical needs [5].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices by Vanda Pharmaceuticals Inc. and its officers or directors, following a negative FDA decision regarding the approval of HETLIOZ for jet lag disorder [1][3]. Group 1: FDA Decision and Market Reaction - On January 8, 2026, Vanda announced that the FDA concluded the supplemental New Drug Application for HETLIOZ could not be approved in its current form, despite acknowledging positive efficacy from clinical trials [3]. - The FDA's decision was based on the view that the clinical trial protocols did not adequately simulate actual jet travel conditions, which involve additional factors such as reduced oxygen pressure and environmental changes [3]. - Following the announcement, Vanda's stock price dropped by $1.20 per share, a decline of 14.05%, closing at $7.34 per share on the same day [3]. Group 2: Legal Investigation - Pomerantz LLP is actively investigating claims on behalf of Vanda's investors, suggesting potential legal action related to the company's business practices [1]. - Investors are encouraged to contact Pomerantz LLP for more information regarding the class action [2][6]. Group 3: Pomerantz LLP Overview - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of recovering significant damages for victims of securities fraud and corporate misconduct [4]. - The firm has been involved in the field of securities class actions for over 85 years, continuing the legacy of its founder, Abraham L. Pomerantz [4].